May 21, 2008Open Access
Bivalirudin during Primary PCI in Acute Myocardial Infarction
Structured PICO
Does bivalirudin alone reduce 30-day rates of major bleeding and net adverse clinical events in patients with ST-segment elevation myocardial infarction who are undergoing primary PCI?
P
Population
Patients with ST-segment elevation myocardial infarction who are undergoing primary PCI
I
Intervention
Anticoagulation with bivalirudin alone
C
Comparator
Heparin plus glycoprotein IIb/IIIa inhibitors
O
Outcome
30-day rates of major bleeding and net adverse clinical eventscomposite
In STEMI patients undergoing primary PCI, bivalirudin alone significantly reduces 30-day major bleeding and net adverse clinical events compared to heparin plus glycoprotein IIb/IIIa inhibitors.
Abstract
In patients with ST-segment elevation myocardial infarction who are undergoing primary PCI, anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events. (ClinicalTrials.gov number, NCT00433966 ClinicalTrials.gov.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Gregg W. Stone
Interventional Cardiology
Bernhard Witzenbichler
Interventional Cardiology
G
Giulio Guagliumi
Interventional Cardiology
Journals
New England Journal of Medicine
Actions
Institutions
Cornell University
Charité - Universitätsmedizin Berlin
Mayo Clinic in Arizona
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...